SEC Filing Analysis: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Executive Vice President sells approximately $1.87M in stock, reducing direct holdings by ~21%.
• Market Impact: Neutral; transaction size is immaterial relative to market capitalization and float.

Company Information

Field	Value
Company	TEVA PHARMACEUTICAL INDUSTRIES LTD
Ticker Symbol	TEVA
CIK	0000818686
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Sabag Mark
CIK	0001721442
Title/Position	Executive Vice President, International Markets Commercial
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-03-17
Transaction Code	S (Sale)
Security Type	Ordinary Shares
Shares Involved	62,102
Price Per Share	$30.141
Total Value	$1,871,816.38
Shares Owned After	224,940
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,871,816.38
% of Market Cap	0.0017%
Shares Transacted	62,102
% of Shares Outstanding	0.0053%
Post-Transaction Ownership	224,940 shares (0.019% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market cap of $109.17 billion, a $1.87 million transaction is quantitatively negligible.
• Ownership Concentration: The insider retains 224,940 shares. This sale represents roughly 21.6% of their pre-transaction holding (287,042 shares).
• Transaction Significance: The transaction falls well below the 0.1% threshold for market cap impact, classifying it as low significance for the broader market.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: While the dollar value is substantial for an individual, it represents a microscopic fraction of Teva's daily liquidity and total valuation. It does not signal a shift in corporate outlook.

Volume & Sentiment

• Expected Volume Impact: None.
• Sentiment Indicator: Neutral. Executive sales for liquidity or diversification are common and do not necessarily indicate a lack of confidence in the firm.

Additional Context

Transaction Notes

• Pricing: Shares were sold at a weighted average price of $30.141 (range $30.115 - $30.215).
• Security: Ordinary Shares may be represented by American Depositary Shares (ADS).